City of Hope Medical Center
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, City of Hope Medical Center sits in the top decile of US sponsors by registered trial count (#59 of 15,742 sponsors by registered trial count).
City of Hope Medical Center: 582 sponsored US clinical trials, 167 recruiting.
City of Hope Medical Center sponsors 582 registered US clinical trials on ClinicalTrials.gov, 167 of them currently recruiting, and 217 completed. 9 of these trials are in Phase 3-4 (later-stage) and 382 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Acute Myeloid Leukemia, with 22 trials.
Top-decile sponsor footprint
City of Hope Medical Center ranks in the top decile of sponsors by registered trial count (#59 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
217 of 245 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (88.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
582 total, page 8 of 12
Cancer Pain Rehabilitation Program to Reduce Pain Related Distress, and Reliance of Pain Medication Through Multimodal Nonpharmacological Solutions
NCT05036408
Telehealth Exercise Platform to Reduce Frailty After Bone Marrow Transplant
NCT04968119
Lung Cancer Risk Assessment and Etiology
NCT06328621
Leflunomide for the Treatment of Relapsed or Refractory CD30+ Lymphoproliferative Disorders
NCT04463615
Microbial Diversity Between Inflamed and Non-inflamed Skin of Patients With Immune Checkpoint Inhibitor-Induced Dermatitis
NCT04812197
Leflunomide for the Treatment of Severe COVID-19 in Patients With a Concurrent Malignancy
NCT04532372
Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies
NCT04681105
SARS-CoV-2 Donor-Recipient Immunity Transfer
NCT04666025
An Imaging Agent (I-124 M5A) in Detecting CEA-Positive Liver Metastases in Patients With Colorectal Cancer
NCT03993327
Family Caregivers in Underserved Populations Providing Complex Cancer Care
NCT05213078
Yttrium Y 90 Basiliximab and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Mature T-cell Non-Hodgkin Lymphoma
NCT02342782
Regorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal Cancer
NCT04362839
Perioperative Ostomy Self-Management Telehealth for Cancer Patients and Family Caregivers
NCT03970070
Remote Telemonitoring of Patient-Generated Physiologic Health Data and Patient-Reported Outcomes
NCT04501913
68Ga-PSMA-11 PET for the Diagnosis of Biochemically Recurrent Prostate Cancer
NCT04216134
CBM588, Nivolumab, and Ipilimumab in Treating Patients With Stage IV or Advanced Kidney Cancer
NCT03829111
IRX-2, Cyclophosphamide, and Pembrolizumab in Treating Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Cancer
NCT03918499
Remotivation Process for Improving Adherence to Lymphedema Treatment Programs in Patients With Breast Cancer-Related Lymphedema
NCT04465253
Geriatric and Quality of Life Assessments in Older Patients With Non-metastatic or Metastatic Head and Neck or Lung Cancer Undergoing Surgery or Chemoradiation and Their Caregivers
NCT03902535
Ipatasertib in Combination With Carboplatin, Carboplatin/Paclitaxel, or Capecitabine/Atezolizumab in Treating Patients With Metastatic Triple Negative Breast Cancer
NCT03853707
Conquer Fear SUPPORT Intervention in Supporting Patients With Stage III-IV Lung or Gynecologic Cancer
NCT03776253
Predicting the Efficacy in Advanced Gastric Cancer.
NCT06490055
Systemic Light Exposure in Preventing Frailty in Older Patients With Prostate Cancer on Hormonal Therapy
NCT03661437
Venetoclax and Romidepsin in Treating Patients With Recurrent or Refractory Mature T-Cell Lymphoma
NCT03534180
Ribociclib and Aromatase Inhibitor in Treating Older Participants With Hormone Receptor Positive Metastatic Breast Cancer
NCT03477396
Trametinib and Trifluridine and Tipiracil Hydrochloride in Treating Patients With Colon or Rectal Cancer That is Advanced, Metastatic, or Cannot Be Removed by Surgery
NCT03317119
Avelumab, Utomilumab, Rituximab, Ibrutinib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma
NCT03440567
Copper 64Cu-DOTA-Daratumumab Positron Emission Tomography in Diagnosing Patients With Relapsed Multiple Myeloma
NCT03311828
Walking for Recovery From Surgery in Improving Quality of Life in Older Adults With Lung or Gastrointestinal Cancer and Their Family Caregivers
NCT03267524
Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic Leukemia
NCT02948283
Comic Art Creation as Supportive Care in Cancer Patients and Caregivers
NCT03067766
Durvalumab and Tremelimumab in Treating Patients With Microsatellite Stable Metastatic Colorectal Cancer to the Liver
NCT03005002
Education as an Intervention of Compassion Fatigue
NCT03212417
Pembrolizumab and Enobosarm in Treating Patients With Androgen Receptor Positive Metastatic Triple Negative Breast Cancer
NCT02971761
High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant
NCT03128359
Brentuximab Vedotin, Cyclosporine, and Verapamil Hydrochloride in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
NCT03013933
Personalized Dietary Intervention in Managing Bowel Dysfunction and Improving Quality of Life in Stage I-III Rectosigmoid Cancer Survivors
NCT03063918
Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRalpha-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple Negative Breast Cancer
NCT02996825
Extracorporeal Photopheresis and Low Dose Aldesleukin in Treating Patients With Steroid Refractory Chronic Graft-Versus-Host Disease
NCT03007238
Neratinib in Treating Older Patients With Stage IV HER2-Positive Breast Cancer
NCT02673398
Ruxolitinib Phosphate and Chemotherapy Given Before and After Reduced Intensity Donor Stem Cell Transplant in Treating Patients With Myelofibrosis
NCT02917096
Probiotic Yogurt Supplement in Reducing Diarrhea in Patients With Metastatic Kidney Cancer Being Treated With Vascular Endothelial Growth Factor-Tyrosine Kinase Inhibitor
NCT02944617
Pembrolizumab and Palliative Radiation Therapy in Treating Patients With Metastatic Esophagus, Stomach, or Gastroesophageal Junction Cancer
NCT02830594
Ibrutinib and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
NCT02744612
Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer
NCT02648477
FOLFIRI and Panitumumab in Treating Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer
NCT02508077
Pancreatic Nutritional Program for Weight Loss in Overweight/Obese Patients With Stage I-III Breast Cancer
NCT02432950
Leflunomide in Treating Patients With Relapsed or Refractory Multiple Myeloma
NCT02509052
COMFORT Caregiver Intervention in Improving Communication and Reducing Distress in Caregivers of Patients With Lung Cancer
NCT02603367
Culturally Adapted Parenting Intervention for Spanish-Speaking Parents in Improving Outcomes of Younger Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia Survivors at Risk for Late Neurocognitive Effects
NCT02559557
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 240 |
| Phase 2 | 142 |
| Phase 3 | 8 |
| Phase 4 | 1 |
Therapeutic Areas
What is open in the City of Hope Medical Center pipeline
167 recruiting of 582 indexed (29% open); 217 completed (37%).
Phase mix: 9 late (III/IV) vs 382 early (I/II) (early-phase heavy).
Top condition: Acute Myeloid Leukemia (22 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
City of Hope Medical Center: open-pipeline peers nationwide
Peers matched on 582 registered trials and 29% open enrollment, not the therapeutic-area sidebar.
City of Hope Medical Center sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 582 trials (± recruiting share)
- Bayer · 591 trials · 4% recruiting
- Janssen Research & Development · 593 trials · 11% recruiting
- Children's Hospital Medical Center, Cincinnati · 571 trials · 19% recruiting
- National Institute of Neurological Disorders and Stroke (NINDS) · 567 trials · 8% recruiting
Sponsors near 29% open enrollment (± trial volume)
- Methodist Health System · 29% recruiting · 125 trials
- 89bio · 29% recruiting · 7 trials
- Alabama Physical Therapy & Acupuncture · 29% recruiting · 14 trials
- AlloSource · 29% recruiting · 7 trials
Related
What to do with this City of Hope Medical Center page
582 registered trials is a research-attention snapshot, not an endorsement of City of Hope Medical Center or any single study.
- 167 of City of Hope Medical Center's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Acute Myeloid Leukemia is the condition City of Hope Medical Center studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Acute Myeloid Leukemia trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. City of Hope Medical Center pipeline card: 582 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.